This 2021 review evaluates the long-term efficacy and safety of FDA-approved anti-obesity medications, including orlistat, lorcaserin, phentermine/topiramate, naltrexone/bupropion, and liraglutide. The authors analyzed clinical trial data to assess weight loss outcomes, adverse effects, and cardiovascular safety profiles. Findings indicate that all reviewed medications contribute to modest weight loss, with phentermine/topiramate
